Health
WHO Issues First Global Guideline on GLP-1 Therapies for Obesity Treatment
WHO Issues First Global Guideline on GLP-1 Therapies for Obesity Treatment
The World Health Organisation (WHO) has released its first-ever guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity, a condition affecting more than 1 billion people worldwide.
Announcing the development on its official X handle on Tuesday, the global health body cautioned that medication alone cannot solve obesity, stressing that drugs must complement healthy diets, regular physical activity, and sustained medical support.
The WHO noted that obesity—responsible for 3.7 million global deaths in 2024—remains a growing crisis, with projections indicating the number of affected individuals could double by 2030 if urgent action is not taken.
According to the organisation, obesity is defined as having a Body Mass Index (BMI) of 30 or above in adults. It is a complex, chronic disease linked to major noncommunicable diseases including cardiovascular disease, type 2 diabetes, several cancers, and increased complications from infectious diseases.
The new guideline focuses on GLP-1 receptor agonists, a class of medicines that lower blood sugar, promote weight loss, and reduce risks of heart and kidney complications. These drugs were added to the WHO Essential Medicines List in September 2025 for managing type 2 diabetes in high-risk patients.
READ ALSO:
- Nigerian Army Rescues Six Kidnap Victims in Kogi as Troops Intensify Operations Against Bandits
- Adeleke to Join New Party Before December 13 — Osun Govt
- BREAKING: Adebayo Adedamola Wins PDP Ticket for 2026 Osun Governorship Election
WHO explained that its conditional recommendations for GLP-1 therapies aim to support adults living with obesity as part of a comprehensive treatment plan, emphasizing the need for behavioral interventions such as healthy eating and consistent physical activity.
WHO Director-General, Dr Tedros Ghebreyesus, said obesity remains a worldwide health threat requiring sustained and equitable care.
“Our new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care. While medication alone won’t solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce related harms,” he said.
Ghebreyesus also warned that the global economic cost of obesity could reach US$3 trillion annually by 2030, adding that the guideline aims to reduce soaring healthcare costs tied to obesity-related complications.
The key recommendations state that GLP-1 therapies may be used for long-term obesity treatment in adults, excluding pregnant women, and must be combined with intensive lifestyle interventions.
The WHO flagged concerns over limited long-term safety data, high drug costs, weak health-system capacity, and the risk of widening health inequalities, stressing that without targeted policies, access to GLP-1 therapies may deepen existing disparities.
It called for a comprehensive obesity strategy built on three pillars:
– Creating healthier environments through strong public policies
– Protecting high-risk individuals through early screening and intervention
– Ensuring equitable access to lifelong, person-centred obesity care
The organisation urged countries to ensure fair access to GLP-1 therapies, strengthen health systems ahead of their broader use, and adopt holistic measures to combat the escalating obesity crisis.
WHO Issues First Global Guideline on GLP-1 Therapies for Obesity Treatment
Health
NCDC Raises Alarm as 37 Health Workers Contract Lassa Fever in 2026
NCDC Raises Alarm as 37 Health Workers Contract Lassa Fever in 2026
The Nigeria Centre for Disease Control and Prevention (NCDC) has confirmed that six healthcare workers contracted Lassa fever within one week, raising renewed concerns about occupational exposure among frontline medical personnel as Nigeria continues to battle the viral disease.
The agency disclosed this in its Lassa Fever Situation Report for Epidemiological Week 9, covering February 23 to March 1, noting that the infections occurred while healthcare workers were involved in treating and managing patients across affected states.
According to the report, 37 healthcare workers have been infected with Lassa fever in 2026 so far, underscoring the risks faced by medical personnel working in treatment centres and hospitals handling suspected cases.
The NCDC said 65 confirmed Lassa fever cases were recorded during the week, representing a slight decline from the 77 cases reported in the previous week. The infections were reported in Benue, Ondo, Bauchi, Taraba, Edo, Plateau and Nasarawa states.
During the same period, 460 suspected cases were reported, while nine deaths occurred among confirmed cases, representing a Case Fatality Rate (CFR) of 13.9 per cent.
READ ALSO:
- AfDB Approves $5.52m Grant to Boost Tax Administration Across West Africa
- BREAKING: Several Passengers Injured as Abuja–Kaduna Train Derails After Collision
- Saudi Intercepts 63 Drones as Iran Denies Responsibility, Blames US, Israel
Cumulatively, the agency said Nigeria has recorded 2,446 suspected cases and 469 confirmed infections in 2026, with 109 deaths recorded so far.
This brings the overall case fatality rate to 23.2 per cent, which is significantly higher than the 18.7 per cent recorded during the same period in 2025, raising concerns among public health experts about the severity of the outbreak this year.
The NCDC noted that 18 states and 69 Local Government Areas have reported at least one confirmed case of the disease in 2026.
However, five states account for the majority of infections, with Bauchi, Ondo, Taraba, Benue and Edo responsible for 86 per cent of confirmed cases nationwide.
Public health authorities attributed the rising fatalities partly to late presentation of patients at health facilities, poor health-seeking behaviour, and low awareness levels in some high-burden communities.
In response, the NCDC said it has activated a multi-partner Incident Management System to coordinate nationwide response activities.
These include active case searches, contact tracing, risk communication campaigns, the distribution of personal protective equipment (PPE) to health facilities, and the deployment of rapid response teams to affected states.
The agency also urged healthcare workers to maintain a high index of suspicion for Lassa fever, especially in endemic areas, and to strictly follow infection prevention and control protocols to reduce hospital-based transmission.
Lassa fever is an acute viral haemorrhagic illness caused by the Lassa virus, first identified in 1969 in the town of Lassa in present-day Borno State.
According to the World Health Organization (WHO), the disease is endemic in Nigeria and several West African countries and is primarily spread by the multimammate rat (Mastomys natalensis).
Humans typically become infected through contact with rodent urine or droppings contaminating food, household items, or surfaces. Human-to-human transmission can also occur, particularly in healthcare settings where adequate infection prevention measures are not followed.
Health experts note that while many infections remain mild or asymptomatic, about 20 per cent of cases develop severe illness, which may include high fever, bleeding, respiratory distress, organ failure, and neurological complications.
Authorities continue to advise Nigerians to maintain proper food storage, improve sanitation, and avoid contact with rodents, while encouraging early medical attention for suspected symptoms in order to reduce fatalities.
NCDC Raises Alarm as 37 Health Workers Contract Lassa Fever in 2026
Health
Nigeria to Receive Breakthrough HIV Prevention Drug This Month – NACA
Nigeria to Receive Breakthrough HIV Prevention Drug This Month – NACA
Nigeria is set to receive Lenacapavir, a groundbreaking HIV prevention drug, in March 2026, the National Agency for the Control of AIDS (NACA) has announced.
The agency disclosed that regulatory approval has been granted by the National Agency for Food and Drug Administration and Control (NAFDAC), clearing the way for the drug’s introduction and nationwide rollout. The confirmation was contained in a statement issued on Monday by Toyin Aderibigbe, Head of Public Relations at NACA.
Lenacapavir, a long-acting injectable HIV prevention drug, has demonstrated 100 percent effectiveness in preventing HIV infection during advanced clinical trials. Unlike daily oral pre-exposure prophylaxis (PrEP) pills, the injectable medication is administered only twice a year, offering a more convenient and discreet prevention option.
NACA said the Federal Government has intensified preparations for the rollout of injectable PrEP in Nigeria, describing the initiative as a critical step toward reducing new HIV infections and strengthening national prevention strategies.
According to the agency, Lenacapavir will be made available at an affordable annual cost of about $40 per person, following voluntary licensing agreements with generic manufacturers. This pricing structure will apply across Nigeria and 119 other low- and middle-income countries, significantly expanding access to the drug.
READ ALSO:
- Iran Retaliates: Gulf States Allied With US Hit by Missiles, Drones
- Islamic Leader Warns Tinubu: State Police Could Be Used Against Opponents
- Daddy Freeze Warns Couples Over 40: ‘Avoid Moving Abroad, Especially US, UK’
“The Government of Nigeria is advancing preparations for the introduction and rollout of lenacapavir as pre-exposure prophylaxis (PrEP). This underscores our commitment to strengthen HIV prevention and accelerate progress toward epidemic control,” the statement said.
As part of readiness efforts, NACA revealed that landscape and preparedness assessments have been completed in 10 states — Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, Gombe, Kano, Kwara, Lagos, and the Federal Capital Territory (FCT) — alongside regulatory clearance by NAFDAC.
Nigeria currently has an estimated 1.9 million people living with HIV, with a national prevalence rate of 1.3 percent among adults aged 15 to 49. In 2021, the country recorded 74,000 new HIV infections and 51,000 AIDS-related deaths, according to official data.
Women aged 15 to 49 are more than twice as likely as men to be living with HIV, while the South-South region bears the highest burden, with an HIV prevalence rate of 3.1 percent.
Health authorities say the arrival of Lenacapavir in Nigeria could mark a major turning point in HIV prevention, particularly for high-risk populations, as the country intensifies efforts to achieve long-term epidemic control.
Nigeria to Receive Breakthrough HIV Prevention Drug This Month – NACA
Health
Popular Brain Supplement Amino Acid May Reduce Longevity in Men
Popular Brain Supplement Amino Acid May Reduce Longevity in Men
A massive study of more than 270,000 people has revealed that higher blood levels of tyrosine, a common amino acid found in protein-rich foods and popular focus-boosting supplements, are associated with shorter life expectancy in men. Researchers suggest that men with elevated tyrosine levels could live nearly one year less on average than those with lower levels, sparking questions about the long-term health effects of both diet and supplements.
The study, led by scientists from the University of Hong Kong and the University of Georgia, analyzed health, genetic, and biochemical data from participants in the UK Biobank, one of the largest population-based studies in the world. The researchers focused on tyrosine and phenylalanine, two amino acids essential to metabolism and neurotransmitter production, including dopamine, which plays a key role in mood, motivation, and cognitive performance.
READ ALSO:
- Amnesty Exposes Alleged Torture, Extortion, Deaths at Imo Police Tiger Base
- REVEALED: How Dispute Over VIP Police Protection, State Policing Led to Egbetokun’s Exit as IGP
- Super Eagles Goalkeeper Suspended Over Match-Fixing Allegation
Using observational and genetic modeling techniques, the researchers found that while phenylalanine had no consistent effect on lifespan, tyrosine showed a clear and potentially causal link to reduced life expectancy in men. No similar association was observed in women, suggesting that biological and hormonal differences may influence how tyrosine affects aging in men versus women.
Scientists are still investigating why tyrosine might impact longevity. One possible explanation is insulin resistance, a risk factor for age-related diseases, which tyrosine may influence. Another theory involves stress-related neurotransmitters and hormonal pathways that may react differently in men, potentially explaining why the effect was sex-specific.
Although the study did not directly test tyrosine supplements, it raises questions about their long-term safety, particularly for men who may already have high systemic levels. Nutrition experts advise moderation and recommend monitoring protein intake. Common dietary sources of tyrosine include beef, pork, lamb, chicken, turkey, salmon, tuna, mackerel, shrimp, lobster, eggs, dairy, soy, whole grains, nuts, and seeds.
The researchers emphasized the need for further studies to confirm these findings, understand the mechanisms linking tyrosine to male longevity, and explore whether dietary or lifestyle interventions could safely reduce tyrosine levels and promote healthy aging.
Popular Brain Supplement Amino Acid May Reduce Longevity in Men
-
Railway1 day agoBREAKING: Several Passengers Injured as Abuja–Kaduna Train Derails After Collision
-
metro23 hours agoCourt Screens Video Showing NDLEA Allegedly Helping Cocaine Smugglers at Enugu Airport
-
International2 days agoIran–Israel Conflict Escalates As IRGC Threatens To Kill Netanyahu
-
International3 days agoOld Dominion University Shooting: Terrorism Suspect Had Links to Nigeria-Based ISIS
-
metro1 day agoTinubu Orders Nationwide Free Rice Distribution for Ramadan, Lent Support
-
International2 days agoNetanyahu dispels death rumours, appears in video from Coffee Shop
-
metro3 days agoLagos reintroduces monthly sanitation as waste, flood risks mount
-
metro1 day agoPolice Launch Forensic Investigation Into Fatal Osogbo Shooting


